2023年2月20日

二期試驗進行評估Trodelvy單藥治療或聯合治療病人的工作。膀胱移行細胞癌是最常見的一種癌症。信貸:CoRus13 / commons.wikimedia.org。基科學報道積極更新數據從三個軍團的二期TROPHY-U-01臨床試驗Trodelvy (sacituzumab govitecan-hziy)治療轉移性移行細胞癌患者(中央),最常見的類型的膀胱癌。基於這些結果,觀察到first-in-class, Trop-2導演抗體藥物共軛產生快速、以及耐用,反應不易治愈類型的一係列mUC包括platinum-ineligible和進步,post-platinum中央。全球的多中心、非盲、multi-cohort,隨訪時間進行第二階段試驗評估Trodelvy作為單藥治療或聯合治療在民大病人采用含鉑方案和進展anti-PD-1 / PD-L1-based免疫療法。群1的試驗是評價Trodelvy進展後以鉑為基礎的化療和檢查點抑製劑(CPI)治療。試驗的組2、3、4、5正在進行。在隊列2中,Trodelvy單方platinum-ineligible患者的評估進展anti-PD-1 / PD-L1-based免疫療法。組3正在評估它在快速進步鉑類治療後患者的進展工作。 Cohorts 4 and 5 in the trial are evaluating Trodelvy combination therapy in treatment naive mUC patients, with subjects in cohort 4 receiving cisplatin and Cohort 5 receiving cisplatin and avelumab, in addition to Trodelvy. Gilead Oncology senior vice-president, therapeutic area head Bill Grossman said: “The TROPHY-U-01 data show consistent benefit of Trodelvy across multiple types of metastatic urothelial cancer, including the most difficult-to-treat and, often times, frail patients where treatment options are still scarce. “Trodelvy has the potential to become a cornerstone treatment in metastatic urothelial cancer, and we are excited about the expected results from the ongoing Phase III TROPiCS-04 study that may serve to convert our US accelerated approval to full approval for Trodelvy to treat patients with locally advanced or metastatic urothelial cancer following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor.” Last month, Gilead Sciences partnered with Strata Oncology to provide Trodelvy for eligible cancer patients in the Strata PATH trial. Share this article